



# INDEX

## A

Account alignment, 60  
Accumulator. *See* Software accumulator  
Actual acquisition cost (AAC), 10, 11, 24, 43  
Acute care hospitals, 8  
Admission, discharge, transfer feeds, 56  
Advanced 340B Operations Certificate, 4  
Affordable Care Act (ACA), 8-9, 17, 20, 30, 44, 231  
Agreement access, 29  
Alliance for Integrity and Reform of 340B, 9  
Alternative methods demonstration projects (AMDPs), 8  
Ambulatory infusions, 155-156  
Anesthetic gases, 21, 78  
Apexus, 11, 20, 40, 80, 175  
Auditable records, 20, 26  
Audits, 29, 30-31  
    annual, 244  
    manufacturer, 236-237  
    policies and procedures, 100-101  
Average manufacturer price (AMP), 44-45, 230  
Average sales price (ASP), 12

## B

Bar-code medication administration, 58  
Benchmarking, 184, 244  
Billing policies, 104-105  
Bipartisan Budget Act of 2015, 19  
Budget variance analysis, 200  
Business partner selection, 244

## C

California Medicaid (Medi-Cal), 10, 13  
Cancer hospitals/centers. *See* Free-standing cancer hospitals/centers  
Carousel and cabinet automation, 62  
Carve in/carve out, 10  
    election, 23  
    Medicaid and, 43-44  
CDM code, 57  
Ceiling price, 22, 230  
    calculations, 226  
Centers for Medicare and Medicaid Services (CMS). *See also* Medicaid; Medicare  
    Ambulatory Payment Classification Panel, 11  
    covered outpatient drug rule, 11  
    Part B reimbursement, 12  
Central supply centers, 82  
Centralized repackaging center case study, 83-84  
Charge  
    capture of, 178  
    data sources for, 55-56

Chargebacks, 231  
 challenges, resolutions of, 147-148  
 covered entity and, 145  
 data elements in, 143  
 distributor and, 144  
 HRSA Office of Pharmacy Affairs and, 145  
 identifier use in, 140-141, 142-143  
 manufacturer and, 143, 144-145  
 overview of, 139-140, 141  
 special situations for, 146-147

Child site, 40, 42

Children's hospitals, 8, 38-39, 67-68

Clawbacks, 134

Community Oncology Alliance, 229

Compliance, 27, 29  
 framework for, 241

Comprehensive pharmacy services, 28

Consumer Price Index for Urban Consumers (CPI-U), 3

Contract management, 76-77

Contract pharmacies, 8, 28  
 basis for, 26  
 guidance for, 28-29  
 manufacturer considerations for, 234-235

Contract pharmacy  
 agreement development for, 129, 130  
 capturing prior dispensing in, 134  
 cash flow and, 135  
 distributor choice and, 132-133  
 enrollment of, 45  
 example of, 127-128  
 free-standing cancer center and, 164-165  
 HRSA audit and, 213-214, 217  
 inventory claim true-ups, rewinds for, 135  
 inventory considerations in, 133-134  
 negative accumulations in, 136-137  
 one-time orders and, 136  
 oversight of, 29  
 policies and procedures for, 99-100  
 program workings with, 126-127  
 registration of, 29  
 relationship development in, 125-126  
 return to stock with, 136-137  
 returns and, 134  
 Schedule II orders and, 136  
 software sorting, filtering models for, 131-132  
 third-party administrator roles in, 129, 131  
 uninsured, underinsured prescriptions and, 128-129

Contrast media, 21, 78

Controlled substance ordering, 62, 80-81

Cost-to-dispense metric, 120-121

Covered drugs, ceiling price for, 22

Covered entities, 7-8, 13  
 chargebacks and, 145  
 diversion and, 23  
 drug requirements of, 22-23  
 eligibility requirements for, 20  
 self-disclosure and, 238  
 violation penalties for, 26-27

Covered outpatient drug, 21-22, 77, 93-94, 162, 230  
 exceptions to, 60-61

Credit-rebill, 146

Critical access hospitals, 8, 38

## D

Dead accumulations, 81

Department of Veterans Affairs (DVA), 10-11

Direct contracting, for free-standing cancer center, 167

Direct purchase accounts, HRSA audit, 214

Direct purchase vendors, 72-73

Direct purchases, policies and procedures for, 98

Direct vendor ordering platforms, 62

Discounts, 9-10, 13, 44-45, 227

Disproportionate share adjustment percentage, 18, 38

Disproportionate share hospitals, 38  
 GPOs and, 67-68

Dispute resolution, 27

Distributor  
 chargebacks and, 144  
 HRSA audit and, 214  
 partnership management and, 73-74

Diversion (drug), 23, 67, 235

Documentation, 242

Drug  
 catalogs of, 62-63  
 diversion of, 23, 67, 235  
 eligibility of, 21  
 managing shortages of, 81  
 manufacturers of, 9  
 waste management of, 76

Drug replenishment, model, 77  
 limiting definition of, 77-78

Drug Supply Chain Security Act, 97

Duplicate discounts, 23, 29  
 manufacturer considerations and, 236  
 prevention policies for, 104-105

## E

Enhanced group purchasing organization contracts, 77

Expired drugs, 79

External audits, policies and procedures, 101

## F

Fee-for-service, 43

Financial management, 197  
 analyzing budget variance with, 200  
 controlling operating results with, 200  
 forecasting drug expenditures with, 198-199  
 managing cost basics with, 199  
 understanding drug expense with, 198

Food and Drug Administration, orphan drug  
 classifications, 154

FQHC look-alikes, 20, 23

Freedom of choice, 29

Free-standing cancer hospitals/centers, 8, 38, 161  
 billing and, 167  
 contract pharmacy and, 164-165  
 direct contracting and, 167  
 eligibility assessment for, 163-164  
 group purchasing organization and, 67-68, 162  
 hospital-patient relationship in, 163  
 inventory management in, 165-166  
 orphan drugs and, 74, 162, 167-168  
 program sustainability in, 167